

Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	10/731,074	ELODAH ET AL.
	Examiner	Art Unit
	Michael P. Barker	1626

All Participants:

(1) Michael P. Barker.

Status of Application: Pending

(3) _____.

(2) Leslie Aberman.

(4) _____.

Date of Interview: 24 October 2005

Time: 3:26 pm

Type of Interview:

Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

N/A

Claims discussed:

1-21

Prior art documents discussed:

See the attached PTO-892

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed:

1. Amend Claim 1 as follows: Page 27 of the Claims, line 27, delete "C1-C6 hydroxyalkyl," ; Page 28 of the Claims, line 1, delete "HSCH2-,".
2. Amend Claim 7 as follows: Page 30 of the Claims, line 1, after the words "in a mammal", add ", for treatment of thrombosis or fibrinolytic impairment in a mammal, wherein the thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion," (the remainder of Claim 7 is unchanged).
3. Amend Claim 13 as follows: Page 31 of the Claims, line 32, delete "A" and add "The" ; line 32, after the word "method", add "of Claim 7".
4. Cancel Claims 9-12 and 14-21, pp. 31-33 of the Claims.